Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases

xlomafota13 shared this article with you from Inoreader Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases Via radioactive iodine Front Endocrinol (Lausanne). 2021 Mar 12;12:634955. doi: 10.3389/fendo.2021.634955. eCollection 2021. ABSTRACT Radioactive iodine is commonly used for the treatment of different thyroid conditions since the 1940s. The EANM has developed a standard pre-therapeutic procedure to estimate patient specific thyroid uptake at treatment of benign thyroid diseases. The procedure which models the time dependent fractional thyroid uptake is based on a two-compartment fitting system, one repre senting the thyroid and the other the blood. The absorbed dose is however only estimated for the thyroid and not for any other organ in the body. A more detailed biokinetic model for iodine is given by the ICRP and includes an iodide transport in the whole body. The ICRP model has 30 different compartments and 48 transfer coefficients to model the biokinetics of iodide and to model different transfer for inorganic iodide and organic iodine. The ICRP model is a recirculation iodine model, and the optimization is performed on the whole model and not exclusively on the thyroid as in the EANM procedure. Combining the EANM method and the ICRP model gives both patient specific estimations of thyroid uptake and retention and include most organs in the body. The new software gives both an improved patient specific dosimetry for the thyroid and an estimation of the absorbed dose to non-target organs and tissues like kidneys, urinary bladder, stomach wall, and uterus. Using the method describ ed in this paper, the repercussions on the daily routines will be minimal. PMID:33776929 | PMC:PMC7995899 | DOI:10.3389/fendo.2021.634955 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Therapeutic Plasma Exchange in Refractory Hyperthyroidism

xlomafota13 shared this article with you from Inoreader Therapeutic Plasma Exchange in Refractory Hyperthyroidism Via radioactive iodine Eur Thyroid J. 2021 Mar;10(1):86-92. doi: 10.1159/000507019. Epub 2020 Apr 28. ABSTRACT INTRODUCTION: Hyperthyroid patients who are unresponsive to medical treatment remain a challenging clinical problem. OBJECTIVE: The goal of our study was to evaluate the use of therapeutic plasma exchange (TPE) in hyperthyroid patients and their outcome after TPE. METHOD: We retrospectively reviewed 22 patients who underwent TPE for refractory thyrotoxicosis in our institution: 13 wi th Graves' disease, 7 with amiodarone-induced thyrotoxicosis (AIT), 1 with toxic goiter, and 1 pregnant patient with familial nonautoimmune thyrotoxicosis. RESULTS: Before TPE, all patients had severe hyperthyroidism, and antithyroid drugs were either contraindicated or not sufficiently effective to restore euthyroidism promptly. After all the TPEs, free T4 (fT4) decreased significantly by 48% (p = 0.001) and fT3 by 52% (p = 0.0001). The median number of TPE sessions per patient was 4 (range: 1-10). There were no complications during the 91 TPE sessions. Total thyroidectomy with no severe side effects was performed on 16/22 patients and 1 other patient was treated with radioactive iodine. One patient died from severe thyrotoxicosis during medical care. The remaining 4 patients were followed up without any radical treatment. For all 7 patients with AIT, iterative TPE led to a significant clinical improvement, and amiodarone was continued for 1 patient. Available treatments were continued between TPE sessions (cholestyramine for 13 patients [60%] and glucocorticoids for 16 patients [73%]). CONCLUSION: TPE allowed a safe decrease of 50% in thyroid hormone levels, and it should be considered for refractory hyperthyroid patients when medical treatments are contraindicated or have failed to restore euthyroidism, irrespective of the etiology of the thyrotoxicosis. PMID:33777824 | PMC:PMC7983568 | DOI:10.1159/000507019 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients' Perspective beyond the Medical Evaluation

xlomafota13 shared this article with you from Inoreader Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients' Perspective beyond the Medical Evaluation Via radioactive iodine Eur Thyroid J. 2021 Mar;10(1):65-71. doi: 10.1159/000508186. Epub 2020 Jul 13. ABSTRACT BACKGROUND: Lenvatinib (LEN) has shown great efficacy but important toxicity in patients with advanced radioactive iodine-refractory (RAI-R) thyroid cancer (TC); a focused evaluation of its impact on patients' quality of life (QoL) is still lacking. Our prospective study investigated the impact of this drug on QoL in a group of RAI-R TC patients treated at our centre. METHODS: All patients filled in two questionnaires before and during treatment: (1) the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events adapted questionnaire, assessing prevalence, severity, and/or interference on daily activities of the most frequent symptomatic adverse events (AEs) reported in previous clinical trials during therapy with LEN, and (2) the European Quality of Life 5 Dimensions 3 Levels (EQ-5D-3L) questionnaire, providing the EQ-5D index and the EQ visual analogue scale (EQ-VAS). Data from baseline questionnaires were compared with those obtained 3, 6, and 12 months after the start of treatment. RESULTS: In our population (n = 20), an overall increased perception of symptomatic AEs emerged during treatment (statistically significant for abdominal pain, asthenia/fatigue, decreased appetite, and xerostomia). The median EQ-5D index and EQ-VAS scores after 3 months of treatment were lower than at baseline, almost returning to initial value s after 12 months. CONCLUSION: RAI-R TC patients reported a general increase in prevalence and interference on daily activities of symptomatic AEs during therapy with LEN. Self-perceived QoL initially decreased during therapy. However, our data suggest that QoL could be restored after 12 months; this trend might partly reflect the impact of therapy optimisation. PMID:33777821 | PMC:PMC7983562 | DOI:10.1159/000508186 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

microRNA-23 inhibits inflammation to alleviate rheumatoid arthritis via regulating CXCL12

xlomafota13 shared this article with you from Inoreader microRNA-23 inhibits inflammation to alleviate rheumatoid arthritis via regulating CXCL12 Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):459. doi: 10.3892/etm.2021.9890. Epub 2021 Mar 3. ABSTRACT Rheumatoid arthritis (RA) is a common systemic, inflammatory and autoimmune disorder. MicroRNAs (miRs) are strongly associated with the initiation and progression of RA. However, the functions and mechanisms underlying miR-23 in RA are not completely understood. Therefore, the present study aimed to investigate the molecular mechanisms underlying miR-23 in RA. A bioinformatics tool (StarBase) and a wide range of experimental assays, including reverse transcription-quantitative PCR, western blotting, luciferase reporter assays and ELISAs, were performed to investigate the biological role of miR-23 in RA. The results indicated that miR-23 was downregulated and chemokine C-X-C motif ligand 12 (CXCL12) was upregulated in RA samples compared with healthy samples. Furthermore, miR-23 overexpression suppressed inflammation via reducing TNF-α, IL-1β and I L-8 expression levels compared with the NC mimic group. Regarding the underlying mechanism, compared with NC mimic, miR-23 mimic decreased CXCL12 mRNA expression by binding to its 3'-untranslated region. Additionally, CXCL12 overexpression reversed miR-23 mimic-mediated effects on inflammation. NF-κB signaling is associated with inflammation. Therefore, the present study indicated that CXCL12 promoted inflammation by activating NF-κB signaling. In conclusion, miR-23 inhibited inflammation to alleviate RA by regulating CXCL12 via the NF-κB signaling pathway, which may serve as a potential target for the diagnosis and treatment of RA. PMID:33777193 | PMC:PMC7967800 | DOI:10.3892/etm.2021.9890 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice

xlomafota13 shared this article with you from Inoreader Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):418. doi: 10.3892/etm.2021.9862. Epub 2021 Feb 25. ABSTRACT The gut microbiota, which may affect normal physiological and biochemical functions, has an important role in the development of human liver diseases. The aim of the present study was to investigate differences in the gut microbiota between chronic alcoholic fatty liver disease (AFLD) and metabolic-associated fatty liver disease (MAFLD). AFLD was induced by chronic alcohol administration and MAFLD was induced by a Western-style diet in C57BL/6 mice. After 8 weeks, the levels of plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (TC), lipopolysaccharide (LPS), tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β and IL-10 were assessed and H&E staining of mouse liver tissue was performed. High-throughput sequencing of 16S ribosomal DNA from the intestinal contents was used to analy ze the different effects of AFLD and MAFLD on the gut microbiota. Differences in the gut microbiota composition were assessed by the t-test. The results revealed increases in LPS, ALT, AST, TG, IL-1β and TNF-α in the AFLD group. Compared with those in the MAFLD control group, the MAFLD group exhibited increased plasma ALT, TG, TC, IL-6, IL-1β and TNF-α levels and decreased plasma IL-10 levels. In addition, the α- and β-diversities revealed that the AFLD and MAFLD groups exhibited obvious changes in the gut structure (with an increase in abundance in the AFLD group and a decrease in abundance in the MAFLD group). In comparison to the AFLD control group, Enterococcaceae were the most abundant bacteria at the family level and Enterococcus and Streptococcus were the most abundant bacteria at the genus level in the AFLD group. However, in the MAFLD group, Lachnospiraceae was the most abundant at the family level, with increases in Erysipelatoclostridium, Gor donibacter and Streptococcus at the genus level and a decrease in the genus Bifidobacterium. In conclusion, the present study confirmed that the AFLD and MAFLD groups harbored differences in the gut microbiota. The marked differences in the gut microbiota at the family and genus levels may contribute to the development process of FLD. PMID:33777186 | PMC:PMC7967804 | DOI:10.3892/etm.2021.9862 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Protein tyrosine phosphatase receptor-type O expression as a prognostic marker in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A prospective study

xlomafota13 shared this article with you from Inoreader Protein tyrosine phosphatase receptor-type O expression as a prognostic marker in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A prospective study Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):435. doi: 10.3892/etm.2021.9852. Epub 2021 Feb 26. ABSTRACT Optimal clinical indicators are crucial for evaluating the prognosis of patients with acute coronary syndrome (ACS). In the present study, the potential prognostic value of protein tyrosine phosphatase receptor-type O (PTPRO) expression in the peripheral blood mononuclear cells of patients with ACS undergoing percutaneous coronary intervention (PCI) was investigated. Patients diagnosed with ACS were prospectively recruited, and PTPRO expression in mononuclear cells separated from peripheral blood was assessed by western blotting. The prognosis was judged by the occurrence of major adverse cardiovascular events. Cox regression analyses were performed to assess the association between PTPRO expression and prognosis. In the enrolled 185 patients with ACS, PTPRO expression was lower after PCI compared with that before PCI (P<0.05). Although the pre- PCI PTPRO expression did not differ significantly between the good and poor prognosis groups, PTPRO expression after PCI was significantly lower in the good prognosis group compared with the poor prognosis group (P<0.05). The area under the receiver operating characteristic curve for the prognostic value of post-PCI PTPRO expression was significantly greater than that for pre-PCI PTPRO expression (P<0.05). Cox regression analysis identified high post-PCI PTPRO expression as an independent risk factor for poor prognosis in patients with ACS (P<0.05), and further analysis indicated that the post-PCI PTPRO expression level was associated with the prognosis of patients with ACS (P<0.05). PTPRO expression in peripheral blood mononuclear cells after PCI is associated with the prognosis of patients with ACS, with high PTPRO expression indicating a high risk of poor prognosis in patients with ACS. PMID:33777188 | PMC:PMC7967798 | DOI:10.3892/etm.2021.9852 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)

xlomafota13 shared this article with you from Inoreader Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 May;21(5):447. doi: 10.3892/etm.2021.9875. Epub 2021 Mar 1. ABSTRACT Duchenne muscular dystrophy (DMD) is the most common degenerative neuromuscular disease. The incidence of DMD in live births is 1/3,600-1/6,000. Although glucocorticoid-dependent medication is the mainstay treatment option for DMD, a standard treatment regimen has yet to be determined. The present review discusses the literature on the timing, methods and courses of glucocorticoid treatment for DMD. The review highlights the importance of the immediate commencement of glucocorticoid treatment following the diagnosis of DMD, with weekend-only administration being advantageous. Adherence to long-term single-glucocorticoid therapy can delay the loss of ambulation ability, and the side effects of the treatment are controllable. However, the standard medication for patients of different ages and stages of disease development, and the use of combination t herapy require further investigation. PMID:33777191 | PMC:PMC7967797 | DOI:10.3892/etm.2021.9875 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.